% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Akradi:1043580,
author = {Akradi, Mohammad and Farzane-Daghigh, Tara and Ebneabbasi,
Amir and Bi, Hanwen and Drzezga, Alexander and Mander, Bryce
A. and Eickhoff, Simon B. and Tahmasian, Masoud},
title = {{H}ow is self-reported sleep-disordered breathing linked
with biomarkers of {A}lzheimer’s disease?},
journal = {Neurobiology of aging},
volume = {154},
issn = {0197-4580},
address = {Amsterdam [u.a.]},
publisher = {Elsevier Science},
reportid = {FZJ-2025-02937},
pages = {16-24},
year = {2025},
note = {Data collection and sharing for this project was funded by
the Alzheimer's Disease Neuroimaging Initiative (ADNI)
(National Institutes of Health Grant U01 AG024904) and DOD
ADNI (Department of Defense award number
W81XWH-12–2–0012). ADNI is funded by the National
Institute on Aging, the National Institute of Biomedical
Imaging and Bioengineering, and through generous
contributions from the following: AbbVie, Alzheimer's
Association; Alzheimer's Drug Discovery Foundation; Araclon
Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb
Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan
Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F.
Hoffmann-La Roche Ltd and its affiliated company Genentech,
Inc.; Fujirebio; GE Healthcare; IXICO Ltd.;Janssen Alzheimer
Immunotherapy Research $\&$ Development, LLC.; Johnson $\&$
Johnson Pharmaceutical Research $\&$ Development LLC.;
Lumosity; Lundbeck; Merck $\&$ Co., Inc.;Meso Scale
Diagnostics, LLC.; NeuroRx Research; Neurotrack
Technologies; Novartis Pharmaceuticals Corporation; Pfizer
Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical
Company; and Transition Therapeutics. The Canadian
Institutes of Health Research is providing funds to support
ADNI clinical sites in Canada. Private sector contributions
are facilitated by the Foundation for the National
Institutes of Health (www.fnih.org). The grantee
organization is the Northern California Institute for
Research and Education, and the study is coordinated by the
Alzheimer's Therapeutic Research Institute at the University
of Southern California. ADNI data are disseminated by the
Laboratory for Neuro Imaging at the University of Southern
California. Author SBE received Helmholtz Imaging Platform
grant (NimRLS, ZT-I-PF-4–010). Author BM currently serves
on a scientific advisory board for AstronauTx.},
abstract = {Sleep-disordered breathing (SDB) is prevalent in
Alzheimer’s disease (AD). Here, we assessed how
self-reported SDB is linked with AD biomarkers, including
amyloid-beta plaque burden (Aβ), regional
fluorodeoxyglucose uptake (rFDG-PET), grey matter volume
(GMV), cognitive scores, and cerebrospinal fluid (CSF)
biomarkers. We selected 757 individuals, including AD, mild
cognitive impairment (MCI), and cognitively unimpaired (CU)
groups, and divided them according to self-reported SDB
condition. Using a stratified subsampling approach, we
selected 512 matched subsamples, and effect sizes (ES) of
the group-SDB interaction were computed for each biomarker
and cognitive score across subsamples. Linear regression
assessed associations between the ES of Aβ, rFDG, and GMV
with the ES of cognitive scores and CSF biomarkers. The
group-SDB interaction had a medium-sized effect on Aβ,
rFDG, and GMV biomarkers in several brain areas.
Participants with SDB exhibited reduced Aβ burden and
increased rFDG uptake in the CU and MCI groups, whereas the
AD group showed elevated Aβ burden and decreased rFDG.
Additionally, SDB+ individuals demonstrated GMV
alterations across all groups. The ES of group-SDB
interaction on Aβ in the precuneus, middle temporal gyrus,
and fusiform gyrus was associated with the ES of cognitive
scores. Taken together, we observed a robust association of
SDB with Aβ pathology in PET and CSF relative to rFDG and
GMV in the AD group, which was also associated with
cognitive decline.},
cin = {INM-7 / INM-2},
ddc = {610},
cid = {I:(DE-Juel1)INM-7-20090406 / I:(DE-Juel1)INM-2-20090406},
pnm = {5251 - Multilevel Brain Organization and Variability
(POF4-525) / 5252 - Brain Dysfunction and Plasticity
(POF4-525)},
pid = {G:(DE-HGF)POF4-5251 / G:(DE-HGF)POF4-5252},
typ = {PUB:(DE-HGF)16},
pubmed = {40582243},
UT = {WOS:001527114100001},
doi = {10.1016/j.neurobiolaging.2025.06.006},
url = {https://juser.fz-juelich.de/record/1043580},
}